Trade Summary

5 days ago, Boulding Mark Elliott, serving as EVP, CLO at Ptc Therapeutics, Inc. (PTCT), sold 3,540 shares at $78.97 per share, for a total transaction value of $279,570.00. Following this transaction, Boulding Mark Elliott now holds 105,212 shares of PTCT.

This sale represents a 3.00% decrease in Boulding Mark Elliott's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, May 8, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 12, 2026, 4 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.